| Dr Christopher Michael Sanders, MD | |
|
100 N Academy Ave, Danville, PA 17822-2170 | |
| (570) 271-6363 | |
| Not Available |
| Full Name | Dr Christopher Michael Sanders |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 17 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457543696 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | MD205377 (Louisiana) | Secondary |
| 208200000X | Plastic Surgery | MD454410 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital - Monroe Campus | Stroudsburg, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Blue Cross Blue Shield of Arizona is launching its 2015 kids cooking contest aimed at motivating Arizona kids to incorporate healthy options into their daily food choices. For the fifth consecutive year, the company is looking for great-tasting, kid-inspired side dishes for the Walk On! Kids Cooking Challenge.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
For medicinal chemists, making tweaks to peptide structures is key to developing new drug candidates. Now, researchers have demonstrated that two iron-containing small-molecule catalysts can help turn certain types of amino acids - the building blocks of peptides and proteins - into an array of potential new forms, even when part of a larger peptide, while preserving a crucial aspect of their chemistry: chirality, or "handedness."
Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.
Cherwell Laboratories have confirmed their continued support for the Pharmaceutical & Healthcare Sciences Society - UCL Q3P Annual Conference 2017.
› Verified 3 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Blue Cross Blue Shield of Arizona is launching its 2015 kids cooking contest aimed at motivating Arizona kids to incorporate healthy options into their daily food choices. For the fifth consecutive year, the company is looking for great-tasting, kid-inspired side dishes for the Walk On! Kids Cooking Challenge.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
For medicinal chemists, making tweaks to peptide structures is key to developing new drug candidates. Now, researchers have demonstrated that two iron-containing small-molecule catalysts can help turn certain types of amino acids - the building blocks of peptides and proteins - into an array of potential new forms, even when part of a larger peptide, while preserving a crucial aspect of their chemistry: chirality, or "handedness."
Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.
Cherwell Laboratories have confirmed their continued support for the Pharmaceutical & Healthcare Sciences Society - UCL Q3P Annual Conference 2017.
› Verified 3 days ago
| Entity Name | Commonwealth Physician Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003238635 PECOS PAC ID: 2668696592 Enrollment ID: O20140617000549 |
News Archive
Blue Cross Blue Shield of Arizona is launching its 2015 kids cooking contest aimed at motivating Arizona kids to incorporate healthy options into their daily food choices. For the fifth consecutive year, the company is looking for great-tasting, kid-inspired side dishes for the Walk On! Kids Cooking Challenge.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
For medicinal chemists, making tweaks to peptide structures is key to developing new drug candidates. Now, researchers have demonstrated that two iron-containing small-molecule catalysts can help turn certain types of amino acids - the building blocks of peptides and proteins - into an array of potential new forms, even when part of a larger peptide, while preserving a crucial aspect of their chemistry: chirality, or "handedness."
Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.
Cherwell Laboratories have confirmed their continued support for the Pharmaceutical & Healthcare Sciences Society - UCL Q3P Annual Conference 2017.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Michael Sanders, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Dr Christopher Michael Sanders, MD 100 N Academy Ave, Danville, PA 17822-2170 Ph: (570) 271-6363 |
News Archive
Blue Cross Blue Shield of Arizona is launching its 2015 kids cooking contest aimed at motivating Arizona kids to incorporate healthy options into their daily food choices. For the fifth consecutive year, the company is looking for great-tasting, kid-inspired side dishes for the Walk On! Kids Cooking Challenge.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
For medicinal chemists, making tweaks to peptide structures is key to developing new drug candidates. Now, researchers have demonstrated that two iron-containing small-molecule catalysts can help turn certain types of amino acids - the building blocks of peptides and proteins - into an array of potential new forms, even when part of a larger peptide, while preserving a crucial aspect of their chemistry: chirality, or "handedness."
Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.
Cherwell Laboratories have confirmed their continued support for the Pharmaceutical & Healthcare Sciences Society - UCL Q3P Annual Conference 2017.
› Verified 3 days ago
Dr. Joseph G. Desantis, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6363 | |
Sean Michael Devitt, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6363 Fax: 570-214-9208 | |
Dr. Thomas J. Bitterly, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6363 |